

Please add new claims 32-43.

--32. (New) A method for treating at least one autoimmune condition in a human subject, said method comprising administering to said subject a therapeutically effective amount of at least one antagonist that binds with a 40 kD subunit, wherein said antagonist is chosen from at least one antibody immunoreactive with the 40 kD subunit and at least one antibody fragment immunoreactive with the 40 kD subunit.

33. (New) The method for treating at least one autoimmune condition of claim 32, wherein the antagonist either

(a) blocks the formation of a heterodimer containing the 40 kD subunit; or
(b) allows the formation of a heterodimer containing the 40 kD subunit, but blocks the activity of said heterodimer.

34. (New) The method of claim 33, wherein the autoimmune condition is chosen from multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

35. (New) The method of claim 33, wherein the autoimmune condition is insulin dependent diabetes mellitus.

36. (New) The method of claim 33, wherein the autoimmune condition is systemic lupus erythematosus.

37. (New) The method of claim 33, wherein the antibody is a monoclonal antibody.

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

38. (New) A method for treating at least one autoimmune condition in a human subject, said method comprising administering to said subject a therapeutically effective amount of at least one antagonist that binds with a 35 kD subunit, wherein said antagonist is chosen from at least one antibody immunoreactive with the 35 kD subunit and at least one antibody fragment immunoreactive with the 35 kD subunit.

39. (New) The method for treating at least one autoimmune condition of claim 38, wherein the antagonist either

(a) blocks the formation of a heterodimer containing the 35 kD subunit; or
(b) allows the formation of a heterodimer containing the 35 kD subunit, but blocks the activity of said heterodimer.

40. (New) The method of claim 39, wherein the autoimmune condition is chosen from multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

41. (New) The method of claim 39, wherein the autoimmune condition is insulin dependent diabetes mellitus.

42. (New) The method of claim 39, wherein the autoimmune condition is systemic lupus erythematosus.

43. (New) The method of claim 39, wherein the antibody is a monoclonal antibody.---

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com